Active Ingredient(s): Olaratumab
FDA Approved: * October 19, 2016
Pharm Company: * ELI LILLY AND CO
Category: Cancer

Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.[1] It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses"). Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 M... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lartruvo 10 mg/ml Intravenous Injection, Solution
NDC: 0002-7190
Eli Lilly and Company
Lartruvo 10 mg/ml Intravenous Solution
NDC: 0002-8926
Eli Lilly and Company